Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.